-
-
-
-
-
-
-
RBC Capital Downgrades Aardvark Therapeutics Inc (AARD) to Sector Perform
-
-
-
-
-
-
-
Raymond James on Aardvark (AARD): 'we think ARD-101’s value proposition as potentially best-in-class
-
-
-
-
-
-
-
Jones Trading Starts Aardvark Therapeutics Inc (AARD) at Buy
-
-
-
-
-
-
-
Aardvark Therapeutics reports positive preclinical data for ARD-201
-
-
-
-
-
-
-
RBC Capital Starts Aardvark Therapeutics Inc (AARD) at Outperform
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

